• Educational resources
  • Events
  • Expert Panel
No matches
  • Cookie policy
  • Privacy policy
  • About us
  • Join ADVENT
  • Contact us

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi | Regeneron Logo

© 2025 Sanofi and Regeneron Pharmaceuticals, Inc.

All rights reserved.
MAT-GLB-2302957 v3.0 11/2023

All Rights Reserved.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: JapanChange country/region
Dermatology

EADV 2025 Congress

ADVENT at EADV 2025: Join Sanofi and Regeneron for three educational symposia on AD, CSU, and BP.
EADV 2025
Past event
17September2025
Location
Paris Expo Porte de Versailles 
1 Pl. de la Prte de Versailles 75015 Paris France

Symposium Details

September 17

Bullous Pemphigoid: Insights and Innovations

Experience this engaging presentation by Profs. Donna Culton, Dedee Murrell, and Ulrike Raap, who will highlight the heterogeneous clinical presentations of BP and its burden, delve beneath the surface into how autoimmunity and predominantly type 2 inflammation mediate the disease, and explore the evolving toolbox of current approaches in BP management.

September 19

The Burden of a Lifetime: Can Disease Modification Rewrite the Narrative of AD?

Join Profs. Jean-David Bouaziz, Amy Paller, and Alan Irvine for a dynamic presentation on the multifaceted burden of atopic dermatitis, the evolving concept of disease modification, and the how targeted systemic therapies may help improve long-term patient outcomes.

September 19

Broadening the Lens: Clinical and Immunological Insights That Inform CSU Management

Experience this engaging presentation by Profs. Martin Metz, Elena Netchiporouk, and Jason Hawkes to explore emerging therapies for chronic spontaneous urticaria.

Location

Paris Expo Porte de Versailles 
1 Pl. de la Prte de Versailles 75015 Paris France
Check on Google Maps
Tags
type 2 inflammationitchheterogeneitydisease modificationbiomarkerscoexisting diseases
MAT-GLB-2503793 - 1.0 - 07/2025